Can IBD be predicted and possibly prevented?

Czech version

Authors: Hradský O.
Authors‘ workplace: Pediatrická klinika 2. LF UK a FN v Motole, Praha
Published in: Gastroent Hepatol 2022; 76(3): 264-267
Category:

Overview

This narrative review summarizes data on prediction and prevention of inflammatory bowel disease (IBD). With increasing incidence, low natural mortality and increasing life expectancy, we can expect IBD that prevalence will soon reach about 1%. This in combination with high therapeutic costs means that IBD represent a significant health problem, which is expected to increase in the near future. The identification of IBD development mechanisms has led to an increasing prediction accuracy. This is opening a new field for therapeutic interventions in early stages of IBD development. We describe some of the essential prediction models and prevention programs that are under way or could be introduced in future.

Keywords:

prevention – Ulcerative colitis – Crohn’s disease – prediction – prevalence – first degree relative

Sources

Burisch J, Vardi H, Schwartz D et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol 2020; 5(5): 454–464. doi: 10.1016/ S2468-1253(20)30012-1.
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5(1): 17–30. doi: 10.1016/ S2468-1253(19)30333-4.
Zhao M, Gönczi L, Lakatos PL et al. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis 2021; 15(9): 1573–1587. doi: 10.1093/ ecco-jcc/ jjab029.
Coward S, Clement F, Benchimol EI et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019; 156(5): 1345–1353.e4. doi: 10.1053/ j.gastro.2019.01.002.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12(12): 720–727. doi: 10.1038/ nrgastro. 2015.150.
Ferrat LA, Vehik K, Sharp SA et al. A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nat Med 2020; 26(8): 1247–1255. doi: 10.1038/ s415 91-020-0930-4.
Herold KC, Bundy BN, Long SA et al. An anti- -CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381(7): 603–613. doi: 10.1056/ NEJMoa1902226.
Torres J, Halfvarson J, Rodriguez-Lago I et al. Results of the seventh scientific workshop of ECCO: precision medicine in IBD-prediction and prevention of inflammatory bowel disease. J Crohns Colitis 2021; 15(9): 1443–1454. doi: 10.1093/ ecco-jcc/ jjab048.
Jostins L, Ripke S, Weersma RK et al. Host- -microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491(7422): 119–124. doi: 10.1038/ nature11582.
de Lange KM, Moutsianas L, Lee JC et al. Genome- wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017; 49(2): 256–261. doi: 10.1038/ ng.3760.
Levine A, Wine E, Assa A et al. Crohn‘s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 2019; 157(2): 440–450.e8. doi: 10.1053/ j.gastro.2019.04.021.
Khalili H, Hakansson N, Chan SS et al. Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn‘s disease: results from two large prospective cohort studies. Gut 2020; 69(9): 1637–1644. doi: 10.1136/ gutjnl-2019-319505.
Xu L, Lochhead P, Ko Y et al. Systematic review with meta-analysis: breastfeeding and the risk of Crohn‘s disease and ulcerative colitis. Aliment Pharmacol Ther 2017; 46(9): 780–789. doi: 10.1111/ apt.14291.
Nguyen LH, Örtqvist AK, Cao Y et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol Hepatol 2020; 5(11): 986–995. doi: 10.1016/ S24 68-1253(20)30267-3.
Papoutsopoulou S, Satsangi J, Campbell BJ et al. Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms. Aliment Pharmacol Ther 2020; 51(12): 1268–1285. doi: 10.1111/ apt.15774.
Khera AV, Chaffin M, Aragam KG et al. Genome- wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018; 50(9): 1219–1224. doi: 10.1038/ s41588-018-0183-z.
Moller FT, Andersen V, Wohlfahrt J et al. Familial risk of inflammatory bowel disease: a population- based cohort study 1977–2011. Am J Gastroenterol 2015; 110(4): 564–571. doi: 10.1038/ ajg.2015.50.
Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017; 389(10075): 1218–1228. doi: 10.1016/ S0140-6736(17)30182-4.
Torres J, Hu J, Seki A et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut 2020; 69(1): 42–51. doi: 10.1136/ gutjnl-2018-317855.
Turpin W, Lee SH, Garay JAR et al. Increased intestinal permeability is associated with later development of Crohn‘s disease. Gastroenterology 2020; 159(6): 2092–2100.e5. doi: 10.1053/ j. gastro.2020.08.005.
Israeli E, Grotto I, Gilburd B et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005; 54(9): 1232–1236. doi: 10.1136/ gut.2004.060228.
Torres J, Petralia F, Sato T et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 2020; 159(1): 96–104. doi: 10.1053/ j.gastro.2020.03.007.
Melinder C, Hiyoshi A, Hussein O et al. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin Transl Gastroenterol 2015; 6(11): e121. doi: 10.1038/ ctg.2015.49.
Lochhead P, Khalili H, Ananthakrishnan AN et al. Association between circulating levels of C-reactive protein and interleukin-6 and risk of inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14(6): 818–824.e6. doi: 10.1016/ j. cgh.2016.01.016.
Lee SH, Turpin W, Espin-Garcia O et al. Anti- -microbial antibody response is associated with future onset of Crohn‘s disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk. Gastroenterology 2021; 161(5): 1540–1551. doi: 10.1053/ j.gastro.2021.07.009.
Kim ES, Tarassishin L, Eisele C et al. Longitudinal changes in fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies. Gastroenterology 2021; 160(4): 1118–1130.e3. doi: 10.1053/ j.gastro.2020.11.050.
Taylor KM, Hanscombe KB, Prescott NJ et al. Genetic and inflammatory biomarkers classify small intestine inflammation in asymptomatic first-degree relatives of patients with Crohn‘ s disease. Clin Gastroenterol Hepatol 2020; 18(4): 908–916.e13. doi: 10.1016/ j.cgh.2019.05. 061.
Spencer EA, Helmus D, Telesco S et al. Inflammatory bowel disease clusters within affected sibships in Ashkenazi Jewish multiplex families. Gastroenterology 2020; 159(1): 381–382. doi: 10.1053/ j.gastro.2020.03.023.
Ng SC, Woodrow S, Patel N et al. Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(4): 725–736. doi: 10.1002/ ibd.21747.
Chan SS, Luben R, Olsen A et al. Body mass index and the risk for Crohn‘s disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol 2013; 108(4): 575–582. doi: 10.1038/ ajg.2012.453.
Brand EC, Klaassen MAY, Gacesa R et al. Healthy cotwins share gut microbiome signatures with their inflammatory bowel disease twins and unrelated patients. Gastroenterology 2021; 160(6): 1970–1985. doi: 10.1053/ j.gastro.2021.01.030.
Halfvarson J, Bodin L, Tysk C et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003; 124(7): 1767–1773. doi: 10.1016/ s0016-508 5(03)00385-8.
Peter I, Maldonado-Contreras A, Eisele C et al. A dietary intervention to improve the microbiome composition of pregnant women with Crohn‘s disease and their off spring: the MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design. Contemp Clin Trials Commun 2020; 18: 100573. doi: 10.1016/ j.conctc.2020.100573.